...
首页> 外文期刊>International Journal of Basic & Clinical Pharmacology >Evaluation of pharmacotherapy in neonatal and pediatric intensive care unit of a south Indian tertiary care hospital: a prospective observational study
【24h】

Evaluation of pharmacotherapy in neonatal and pediatric intensive care unit of a south Indian tertiary care hospital: a prospective observational study

机译:南印度三级护理医院新生儿和儿科重症监护单位的药物疗法评价:一项潜在观察研究

获取原文
           

摘要

Background: Evaluating the pharmacotherapy is essential at neonatal intensive care unit (NICU) and pediatric intensive care unit (PICU) to identify and understand pattern and variability in drug use in polypharmacy, also to promote interventions that will improve patient outcomes.Methods: In our study, we audited pharmacotherapy of 300 neonates and 100 pediatric patients admitted to NICU and PICU from November 2018 to February 2019. WHO-CORE prescribing indicators, WHO-ATC system and WHO-ICD 10th version was used to evaluate pharmacotherapy and to understand the pattern and extent of medication use and to systematically classify drugs and diseases respectively.Results: A total of 1207 medications containing 34 unique active ingredients were prescribed for 300 neonates with an average of 4.02 (±2.0) drugs per neonate admitted to NICU and the most prescribed drugs were anti-infectives for systemic use 799. A total of 976 medications containing 69 unique active ingredients were prescribed with an average of 9.76 (±3.81) per pediatric patients admitted to PICU with anti-infectives for systemic use 331 tops the list. More than 75% of drugs was prescribed in generic name with 98% constant availability of key drugs at intensive care unit.Conclusions: This study substantiates the need for reinforcement of institutional antibiotic policies as antibiotics are widely prescribed and there is an increase trend of antibiotic resistance at critical care unit, assessment of WHO core prescribing indicators are reflective of quality care revealing the awareness about strict monitoring of pharmacotherapy.
机译:背景:评估药物治疗是新生儿重症监护单位(NICU)和儿科重症监护单位(PICU)是必不可少的,以识别和理解药物使用的模式和变异,也促进改善患者结果的干预措施。方法:在我们的研究,从2018年11月到2019年11月,我们审核了300个新生儿和100名儿科患者的药物治疗和100次儿科患者。Who-核心规定指标,世界卫生组织 - ATC系统和WHO-ICD第10版用于评估药物治疗并理解模式和药物的程度使用和系统地分析药物和疾病。结果:每位新生儿的300个新生儿总共含有34种独特的活性成分的1207个药物,每位新生儿每新生儿和最规定的含量为4.02(±2.0)药物药物是系统性使用的抗感染性799.规定了总共含有69种独特的活性成分的976个药物每位儿科患者平均为9.76(±3.81),患有用于Sysicic Usify的抗感染物331顶部列表。超过75%的药物在一般名称中规定,重症监护单位的关键药物有98%的持续可用性。结论:这项研究证实了加强制度抗生素政策的需求,因为抗生素被广泛规定,抗生素呈增加趋势抵抗抵抗在关键护理单位,核心规定指标的评估是质量护理的反映揭示了对严格监测药物治疗的认识。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号